Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial

Next Previous
Trial Profile

Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sugammadex (Primary) ; Atropine; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Sponsors Merck & Co

Most Recent Events

  • 14 Jun 2019 As per NCT and Eudra, the trail is open label, however, result source have reported blinded for the patient and the researcher testing pulmonary function and Reversal medications were unblinded to the anesthesiologist in the operating room. researcher testing pulmonary function was not associated with administration of study drugs. As anesthesiologist was unblinded and patients were blinded I have added "single blind"
  • 04 Jun 2019 Primary endpoint has not been met. (Change from baseline in FVC at 1h after surgery), as reported in an article published in the Canadian Journal of Anesthesia.
  • 04 Jun 2019 Results published in the Canadian Journal of Anesthesia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top